Voyager Therapeutics - Stock Price History | VYGR
Historical daily share price chart and data for Voyager Therapeutics since 2022 adjusted for splits. The latest closing stock price for Voyager Therapeutics as of May 27, 2022 is 6.05.
- The all-time high Voyager Therapeutics stock closing price was 31.31 on March 06, 2018.
- The Voyager Therapeutics 52-week high stock price is 10.60, which is 75.2% above the current share price.
- The Voyager Therapeutics 52-week low stock price is 2.46, which is 59.3% below the current share price.
- The average Voyager Therapeutics stock price for the last 52 weeks is 4.35.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Voyager Therapeutics Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2021 |
4.4749 |
7.2600 |
9.0400 |
2.4700 |
2.7100 |
-62.10% |
| 2020 |
11.1098 |
13.5800 |
14.6600 |
6.8000 |
7.1500 |
-48.75% |
| 2019 |
17.8972 |
9.4200 |
28.2900 |
8.0000 |
13.9500 |
48.40% |
| 2018 |
18.3287 |
17.6300 |
31.3100 |
8.5900 |
9.4000 |
-43.37% |
| 2017 |
12.6593 |
11.9700 |
25.8800 |
8.2400 |
16.6000 |
30.30% |
| 2016 |
12.5015 |
21.1500 |
21.1500 |
8.5600 |
12.7400 |
-41.83% |
| 2015 |
23.0354 |
17.7500 |
30.2000 |
17.5000 |
21.9000 |
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.233B |
$0.037B |
|
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
|
